A detailed history of Vestal Point Capital, LP transactions in Achilles Therapeutics PLC stock. As of the latest transaction made, Vestal Point Capital, LP holds 1,500,000 shares of ACHL stock, worth $1.53 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
1,500,000
Previous 1,500,000 -0.0%
Holding current value
$1.53 Million
Previous $1.88 Billion 34.8%
% of portfolio
0.09%
Previous 0.16%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$0.82 - $1.57 $1.14 Million - $2.19 Million
1,391,917 Added 1287.82%
1,500,000 $1.88 Billion
Q4 2023

Feb 13, 2024

BUY
$0.78 - $0.96 $84,304 - $103,759
108,083 New
108,083 $96.1 Million

Others Institutions Holding ACHL

About Achilles Therapeutics plc


  • Ticker ACHL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,774,000
  • Market Cap $41.6M
  • Description
  • Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...
More about ACHL
Track This Portfolio

Track Vestal Point Capital, LP Portfolio

Follow Vestal Point Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vestal Point Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Vestal Point Capital, LP with notifications on news.